Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.

While corticosteroids and a limited number of nonsteroidal agents have formed the basis for United States Food and Drug Administration (FDA)-approved topical treatments of plaque psoriasis, there remains a need for efficacious nonsteroidal topical therapies in patients with psoriasis who cannot tolerate, do not respond well to, or wish to avoid topical corticosteroid therapy. Aryl hydrocarbon receptor (AhR) modulation has been shown to be an effective mechanism of action in the topical treatment of psoriasis. Currently there is only one FDA-approved, nonsteroidal, topical AhR modulating agent for the treatment of psoriasis. This educational activity seeks to broaden the treatment knowledge of the practicing dermatology community and inform them on the use of topical AhR modulating therapy as an addition to the advancing treatment armamentarium for patients with psoriasis.